Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36497292/
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage non-small cell lung cancer (NSCLC) remains dismal for common relapses after curative surgery, considerable efforts are...
Conclusions: Unanswered questions in perioperative therapy in NSCLC include the optimal sequence and timing of chemotherapy and immunotherapy, the potential of combination strategies, the role of predictive biomarkers for patient selection and the choice of useful endpoints in clinical investigation.
Albert DekkerDecember 30, 20226-18 months and this all will be well established
A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer
Source : https://www.sciencedirect.com/science/article/pii/S156757692200875X?via=ihub
The higher the absolute count of lymphocyte subsets, the longer the overall survival of the NSCLC patients. * The nomogram constructed by the absolute count of lymphocyte subsets can accurately...
Conclusions: " We established a prognostic nomogram to predict OS of the NSCLC patient. This nomogram provided a more quantitative, scientific and objective basis for accurate diagnosis and individual management of NSCLC patients."
Albert DekkerDecember 30, 2022someone would assume that now on patients on clinical trials will need to be radimized based on this nomogram. It would be interesting to see NCCN opinion in this regards
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Source : https://www.jtocrr.org/article/S2666-3643(22)00140-0/fulltext
Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low efficacy in the EGFR-mutant setting....
Conclusions: Immune checkpoint inhibition is ineffective in EGFR TKI–resistant NSCLC. Whereas a small subgroup of EGFR-mutant NSCLC may be immunogenic and responsive to ICI, better biomarkers are needed to select appropriate patients."
Albert DekkerDecember 15, 2022In my opinion it is extremely important as it proves another proof that both AO and IO combos have no activity in this disease
Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies
Source : https://www.sciencedirect.com/science/article/abs/pii/S2212534522001447?via=ihub
Available online 29 November 2022 Author links open overlay panel Tomohiro Tanaka a Person b Envelope Show more This study aimed to investigate whether the immunosenescence-related score is a critical...
Conclusions: High mGPS scores significantly impaired DCR, mPFS, and mOS in patients with advanced NSCLC treated with anti-PD-1 antibodies.
A Subset of VEGFR-TKIs Activates AMPK in LKB1-mutant Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36459496/
The mutation of tumor suppressor gene liver kinase B1 (LKB1) has a prevalence of about 20% in non-small cell lung cancer (NSCLC). LKB1-mutant lung cancer is characterized by enhanced aggressiveness...
Conclusions: This study discovered AMPK as an important off-target of apatinib, and elucidated different effects of this cluster of VEGFR-TKIs on AMPK. This finding can be the basis for the accurate and combined application of these drugs in clinic, and highlights the subset of VEGFR-TKIs including apatinib and anlotinib are potentially valuable in the treatment of LKB1-mutant NSCLC.
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors - Targeted Oncology
Source : https://link.springer.com/article/10.1007/s11523-022-00931-9
Background Heightened signaling by mesenchymal epithelial transition factor (MET) is implicated in tumorigenesis. Glesatinib is an investigational, oral inhibitor of MET and AXL. Objective This phase I study determined the...
Conclusions: The safety profile of single-agent glesatinib was acceptable. SDD 750 mg twice daily was selected as the preferred glesatinib formulation and dose based on clinical activity, safety, and PK data. Observations from this study led to initiation of a phase II study of glesatinib in patients with NSCLC stratified by type of MET alteration (NCT02544633).